摩根大通首予Prelude Therapeutics增持评级,目标价12美元

美股速递
Sep 17

摩根大通近日宣布,正式启动对Prelude Therapeutics公司(股票代码:PRLD)的首次覆盖研究,并授予其"增持"评级。与此同时,该投行设定其目标股价为12美元。这一消息引发市场关注,投资者普遍聚焦于该生物制药企业未来的发展潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10